About US
Contact us
-
FDA could approve 'at least one' COVID-19 vaccine before election: analystWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewherethat could affect drug pricing and how drugmakers operate. About sixmonth2020/6/24
-
It's the end of road for hydroxychloroquine in COVID-19 as Novartis, NIH and WHO pull out of trialsThe road for hydroxychloroquine against COVID-19 is coming to an end. Three major clinical programs have been terminated after a U.K. trial found “no clinical benefit” for the malaria drug championed2020/6/23
-
Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggestsPfizer’s tafamidis arrived in the U.S. in 2019 with a vastly discounted list price over rival transthyretin amyloidosis drugs. But its $225,000-a-year tag still seems too much for many heart patients2020/6/23
-
GlaxoSmithKline recalls children's Robitussin, Dimetapp with faulty dosing cupsBritish drugmaker GlaxoSmithKline was one of many companies forced to pull its version of heartburn med Zantac off shelves last year after a widespread carcinogen scare. Now, GSK is in hot water for2020/6/22
-
Patent loss on MS hit Tecfidera puts pressure on Biogen to score a win in Alzheimer's: analystsNow that the worst-case scenario for Biogen in its Tecfidera patent battle with Mylan has come to pass, Wall Street analysts have a warning for investors: New generic competition to the multiple scle2020/6/22
-
Novavax, advancing COVID-19 shot, recruits AstraZeneca exec as its chief medical officerOn the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team. Joining the company's leadership team as chief m2020/6/19
-
Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritisNovartis and Eli Lilly have been jockeying for new indications and commercial success for their IL-17 inhibitors Cosentyx and Taltz, respectively. Lilly appeared to get the label-expansion edge with2020/6/19
-
U.K. endorses dexamethasone in COVID-19 hours after groundbreaking data releaseRight on the heels of data showingthe decades-old, inexpensive steroid dexamethasone can reduce COVID-19 deaths among hospitalizedpatients requiring oxygen, the U.K. government granteda world-first a2020/6/18
-
Merck, Pfizer's Steglatro rings up CV safety win but still lags heart-helping peersMerck and Pfizer’s Steglatro, late to the SGLT2 party, has been working to catch up to its in-class rivals, which already bear heart-helping approvals. But its cardiovascular outcomes data won’t help2020/6/18
-
AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney functionAstraZeneca’s Farxiga is already getting a speedy FDA review as a treatment for chronic kidney disease (CKD), but it’s still piling on the positive results. A new analysis of the company’s Declare-Ti2020/6/17